HVIVO

hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.

hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).

Leveraging human disease models in flu, RSV, and asthma exacerbation, the hVIVO platform captures ‘disease in motion’, illuminating the entire disease life cycle from healthy to sick and back to health. Via this insight, the platform enables the rational selection of drug targets and biomarkers while simultaneously providing a revolutionary methodology for testing product safety and efficacy. The Company has three clinical stage products currently in development as well as a growing pre-clinical pipeline.